Evanson Asset Management LLC lifted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 23.2% during the 4th quarter, Holdings Channel reports. The firm owned 1,832 shares of the medical research company’s stock after purchasing an additional 345 shares during the period. Evanson Asset Management LLC’s holdings in Amgen were worth $318,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in the company. Baker Ellis Asset Management LLC acquired a new position in shares of Amgen during the third quarter valued at $108,000. Jackson Grant Investment Advisers Inc. lifted its stake in shares of Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 5 shares during the period. Phocas Financial Corp. acquired a new position in shares of Amgen during the second quarter valued at $110,000. Omnia Family Wealth LLC lifted its stake in shares of Amgen by 25.3% during the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after acquiring an additional 147 shares during the period. Finally, Salem Investment Counselors Inc. lifted its stake in shares of Amgen by 4.7% during the second quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock valued at $139,000 after acquiring an additional 36 shares during the period. Institutional investors own 79.50% of the company’s stock.
AMGN has been the topic of several research reports. BidaskClub raised Amgen from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 2nd. Morgan Stanley cut their price target on Amgen from $204.00 to $196.00 and set an “overweight” rating on the stock in a research note on Friday, February 2nd. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $181.60 price target on the stock in a research note on Tuesday, February 27th. Oppenheimer reaffirmed a “buy” rating and set a $205.00 price target on shares of Amgen in a research note on Tuesday, January 30th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $191.72.
Shares of Amgen, Inc. (AMGN) opened at $182.55 on Tuesday. The company has a market capitalization of $135,638.63, a PE ratio of 71.03, a PEG ratio of 2.31 and a beta of 1.37. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a 1 year low of $152.16 and a 1 year high of $201.23.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned $2.89 EPS. research analysts forecast that Amgen, Inc. will post 13.25 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be given a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio is currently 205.45%.
Amgen announced that its board has approved a share buyback program on Thursday, February 1st that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.
In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 4,575 shares of company stock worth $838,064. 0.19% of the stock is currently owned by insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.